 Approaches treatment cytomegalovirus retinitis ganciclovir foscarnet ganciclovir nucleoside analogue foscarnet pyrophosphate analogue cytomegalovirus CMV DNA polymerase inhibit CMV replication plasma concentrations achievable intravenous administration agents similar plasma half-lives kidneys Foscarnet low solubility high degree ionization physiologic pH doses volumes drugs initial induction regimen long-term maintenance regimen patients immune deficiency syndrome AIDS CMV retinitis efficacy long-term maintenance therapy median time progression similar drugs major toxicity ganciclovir myelosuppression dose-limiting neutropenia thrombocytopenia AIDS patients major toxicity foscarnet nephrotoxicity dose-limiting toxicity patients effects foscarnet hypocalcemia seizure arrhythmia Studies vitro additive synergistic inhibitory effect CMV drugs lower-dose combination regimens higher-dose alternating regimens efficacy toxicity drug